Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR

A compound of Formula (A)

• wherein
• R1 is —Z—X—Y, —Z—Y, or —X—Y wherein X is a linker of any of structures L1, L2, L9 or L10
• each Q is independently absent or is C(O), C(O)—NR4, NR4—C(O),O—C(O)—NR4, NR4—C(O)—O, —CH2—, or —O—, wherein at least two carbon atoms separate the —O— from any other heteroatom group;
• each T is independently absent or is alkylene, wherein one or more —CH2— groups of the alkylene, may each independently be replaced with a —O—, wherein the —O— are separated by at least 2 carbon atoms;
• Y is an amino acid sequence, a nucleic acid sequence, or an oligomer, and
• Z is absent;
• each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11,12,13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, wherein if n is greater than 1, each T and each Q of each (T-Q-T-Q) is independently selected;
• R2 is —N(R3)—C(O)—R3 or —N(R3)—C(O)—OR3, and
• each R3 is independently —H, —(C1-C5)alkyl, halo-substituted (C1-C5)alkyl, or (C3-C6)cycloalkyl,
• each R4 is independently-H, —(C1-C20)alkyl, or (C3-C6)cycloalkyl wherein one to six —CH2— groups of the alkyl or cycloalkyl separated by at least two carbon atoms may be replaced with —O—, —S—, or —N(H)—, and wherein the alkyl and cycloalkyl may be substituted with one to six halo atoms;
• and
• or a pharmaceutically acceptable salt thereof.